IL-10 Immunomodulation of Myeloid Cells Regulates a Murine Model of Ovarian Cancer
Overview
Affiliations
Elevated levels of IL-10 in the microenvironment of human ovarian cancer and murine models of ovarian cancer are well established and correlate with poor clinical prognosis. However, amongst a myriad of immunosuppressive factors, the actual contribution of IL-10 to the ovarian tumor microenvironment, the mechanisms by which it acts, and its possible functional redundancy are unknown. We previously demonstrated that elimination of the myeloid-derived suppressor cell (MDSC) compartment within the ovarian tumor ascites inhibited tumor progression and, intriguingly, significantly decreased local IL-10 levels. Here we identify a novel pathway in which the tumor-infiltrating MDSC are the predominant producers of IL-10 and, importantly, require it to develop their immunosuppressive function in vivo. Importantly, we demonstrate that the role of IL-10 is critical, and not redundant with other immunosuppressive molecules, to in vivo tumor progression: blockade of the IL-10 signaling network results in alleviation of MDSC-mediated immunosuppression, altered T cell phenotype and activity, and improved survival. These studies define IL-10 as a fundamental modulator of both MDSC and T cells within the ovarian tumor microenvironment. Importantly, IL-10 signaling is shown to be necessary to the development and maintenance of a permissive tumor microenvironment and represents a viable target for anti-tumor strategies.
Myeloid cells: key players in tumor microenvironments.
Hua Q, Li Z, Weng Y, Wu Y, Zheng L Front Med. 2025; .
PMID: 40048137 DOI: 10.1007/s11684-025-1124-8.
Guo J, Si G, Song X, Si F Medicine (Baltimore). 2024; 103(44):e40374.
PMID: 39496002 PMC: 11537666. DOI: 10.1097/MD.0000000000040374.
Hamze Sinno S, Imperatore J, Bai S, Gomes-Jourdan N, Mafarachisi N, Coronnello C J Clin Invest. 2024; 134(21).
PMID: 39312740 PMC: 11527450. DOI: 10.1172/JCI175147.
Targeting tumor microenvironment for non-small cell lung cancer immunotherapy.
Wang L, Jia Q, Chu Q, Zhu B Chin Med J Pulm Crit Care Med. 2024; 1(1):18-29.
PMID: 39170874 PMC: 11332857. DOI: 10.1016/j.pccm.2022.11.001.
Surico P, Lee S, Singh R, Naderi A, Bhullar S, Blanco T Exp Eye Res. 2024; 242:109871.
PMID: 38527580 PMC: 11055659. DOI: 10.1016/j.exer.2024.109871.